Expression of tissue inhibitor of metalloproteinase-1, -2, and -3 during neointima formation in organ cultures of human saphenous vein

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 2, 1999, Pages 255-265

  Kranzhofer A ^a   Baker, A H ^a   George, S J ^a   Newby, A C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Arteriosclerosis; Coronary artery bypass grafting; Metalloproteinases; Proliferation; Vascular smooth muscle cells

Indexed keywords

METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CELL MIGRATION; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN TISSUE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTENOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAPHENOUS VEIN; TISSUE CULTURE; ZYMOGRAPHY;

EID: 0345628584     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.2.255     Document Type: Article

References (52)

1. Campeau L, Enjalbert M, Lesperance J, Vaislic C, Grondin CM, Bourassa MG. Atherosclerosis and late closure of saphenous vein grafts: sequential angiographic studies 2 weeks, 1 year, 5 to 7 years, and 10 to 12 years after surgery. Circulation. 1983;68(suppl II):II-1-II-7.
2. Angelini GD, Newby AC. The future of saphenous vein as a coronary artery bypass conduit. Eur Heart J. 1989;10:273-280.
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
4. Southgate KM, Davies M, Booth RFG, Newby AC. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem J. 1992;288:93-99.
5. Pauly RR, Passaanti A, Bilato C, Monticone R, Cheng L, Papadopoulos N, Gluzband YA, Smith L, Weinstein C, Lakatta EG, Crow MT. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res. 1994;75:41-54.
6. Galis ZS, Sukhova GK, Kranzhöfer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively express matrix-degrading proteases. Proc Natl Acad Sci U S A. 1995;92:402-406.
7. Hanemaaijer R, Koolwijk P, Le Clercq L, de Vrie WJA, van Hinsbergh VWM. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells: effects of tumour necrosis factor α, interleukin 1 and phorbol ester. Biochem J. 1993;296:803-809.
8. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Unemori EN, Lark MW, Amento E, Libby P. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 1994;75:181-188.
9. Fabumni R, Baker AH, Murray EJ, Booth RF, Newby AC. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors of metalloproteinases-1, -2 and -3 in rabbit aortic smooth muscle cells. Biochem J. 1996;315:335-342.
10. Zaltsman AB, Newby AC. Increased secretion of gelatinases A and B from the aortas of cholesterol fed rabbits: relationship to lesion severity. Atherosclerosis. 1997;130:61-70.
11. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1996;78:38-43.
12. Zempo N, Kenagy RD, Au T, Bendeck M, Clowes MM, Reidy MA, Clowes AW. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J Vasc Surg. 1994;20: 209-217.
13. Southgate KM, Fisher M, Banning AP, Thurston VJ, Fabunmi RP, Baker AH, Groves PH, Davies M, Newby AC. Upregulation of basement-membrane-degrading metalloproteinase secretion following balloon angioplasty of pig carotid arteries. Circ Res. 1996;79:1177-1187.
14. Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res. 1996;78:38-43.
15. Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinases inhibitor. Arterioscler Thromb Vasc Biol. 1996;16:28-33.
16. George SJ, Zaltsman AB, Newby AC. Increased expression of MMP-9 and activation of MMP-2 occur in association with injury and during neointima formation in human saphenous vein organ cultures. Cardiovasc Res. 1997;33:447-459.
17. Southgate KM, Izzat MB, Knight D, Angelini GD. Upregulation of matrix degrading gelatinases in pig saphenous vein grafts. Br Heart J. 1995;73(suppl 3):46. Abstract.
18. George SJ, Newby AC. A metalloproteinase inhibitor (Ro 31-9790) inhibits smooth muscle cell proliferation and migration and neointima formation in human saphenous vein. Eur Heart J. 1996;17:P1062. Abstract.
19. Willenbrock F, Murphy G. Structure-function relationships in the tissue inhibitors of metalloproteinases. Am J Respir Crit Care Med. 1994; 150(suppl):S165-S170.
20. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell-surface activation of 72 kDa type IV collagenase: isolation of the activated form of the membrane metalloproteinase. J Biol Chem. 1995;270:5331-5338.
21. Murphy G, Willenbrock F, Ward RV, Cockett MI, Eaton D, Docherty AJP. The C-terminal domain of 72 kDa gelatinase A is not required for catalysis but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. Biochem J. 1992;283: 636-641.
22. Nikkari ST, Geary RL, Hatsukami T, Ferguson M, Forough R, Alpers CE, Clowes AW. Expression of collagen, interstitial collagenase and tissue inhibitor of metalloproteinase-1 in restenosis after carotid endarterectomy. Am J Pathol. 1996;148:777-783.
23. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94: 2493-2503.
24. Wang H, Moore S, Alavi MZ. Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in rabbit aortic neointima after selective deendothelialisation. Atherosclerosis. 1996;126:95-104.
25. Hasenstab D, Forough R, Clowes AW. Plasminogen activator inhibitor type 1 and tissue inhibitor of metalloproteinases-2 increase after arterial injury in rats. Circ Res. 1997;80:490-496.
26. Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem. 1994;269:9352-9360.
27. Soyombo AA, Angelini GD, Bryan AJ, Jasani B, Newby AC. Intimal proliferation in an organ culture of human saphenous vein. Am J Pathol. 1990;137:1401-1410.
28. Hembry RM, Murphy G, Reynolds JJ. Immunolocalization of tissue inhibitor of metalloproteinases (TIMP) in human cells: characterization and use of specific antiserum. J Cell Sci. 1985;73:105-119.
29. Ward RV, Hembry RM, Reynolds JJ, Murphy G. The purification of tissue inhibitor of metalloproteinases-2 from its 72 kDa progelatinase complex. Biochem J. 1991;278:179-187.
30. Jones SE, Jomary C, Apte SS, Iwata K. Neal MJ. Immunohistochemical analysis of TIMP-3 expression in degenerative retinal disease. Invest Ophthalmol Vis Sci. 1996;37:2257. Abstract.
31. Pederson DC, Bowyer DE. Endothelial injury and healing in vitro: studies using an organ culture system. Am J Pathol. 1985;119:264-272.
32. Soyombo AA, Angelini GD, Bryan AJ, Newby AC. Surgical preparation induces injury and promotes smooth muscle cell proliferation in a culture of human saphenous vein. Cardiovasc Res. 1993;27:1961-1967.
33. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonucleases. Biochemistry. 1979;18:5294-5299.
34. Docherty AJP, Lyons A, Smith BJ, Wright EM, Stephens PE, Harris TJR, Murphy G, Reynolds JJ. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature. 1985;318:66-69.
35. Stetler-Stevenson WG, Brown PD, Onisto M, Levy AT, Liotta LA. Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissue. J Biol Chem. 1990;265:13933-13938.
36. Uria JA, Ferrando AA, Velasco G, Freije JMP, Lopez-Otin C. Structure and expression in breast tumors of TIMP-3, a new member of the metalloproteinase inhibitor family. Cancer Res. 1994;54:2091-2094.
37. Tokunaga K, Nakamura Y, Sakata K, Fujimori K, Ohkubo M, Sawada K, Sakiyama S. Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. Cancer Res. 1987;47:5616-5619.
38. Ward RV, Hembry RM, Reynolds J, Murphy G. The purification of tissue inhibitor of metalloproteinases-2 from its 72 KDa progelatinase complex: demonstration of the biochemical similarities of tissue inhibitor of metalloproteinases-2 and tissue inhibitor of metalloproteinases-1. Biochem J. 1991;278:179-187.
39. Baker AH, Wilkinson GWG, Hembry RM, Murphy G, Newby AC. Development of adenoviruses that drive high level expression of the human metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 genes: characterisation of their infection into rabbit smooth muscle cells and MCF-7 adenocarcinoma cells. Matrix Biol. 1996;15:383-395.
40. Soyombo AA. Organ Culture of Human Saphenous Vein [PhD thesis]. Wales, UK: University of Wales; 1990:101-112.
41. Thyberg J. Differentiated properties and proliferation of arterial smooth muscle cells in culture. Int Rev Cytol. 1996;169:183-265.
42. Edwards DR, Rocheleau H, Sharma RR, Wills AJ, Cowie A, Hassell JA, Heath JK. Involvement of AP-1 and PEA-3 binding sites in the regulation of murine tissue inhibitor of metalloproteinases-1 (TIMP-1) transcription. Biochim Biophys Acta. 1992;1171:41-55.
43. Shi Y, O'Brien JE, Mannion JD, Morrison RC, Chung W, Fard A, Zalewski A. Remodeling of autologous saphenous vein grafts: the role of perivascular myofibroblasts. Circulation. 1997;95:2684-2693.
44. Slomp J, Gittenberger de Groot AC, van Munsteren C, Huysmans HA, van Bockel H, van Hinsbergh VWM, Poelmann RE. Nature and origin of the neointima in whole vessel wall organ culture of the human saphenous vein. Virchows Arch. 1996;428:59-67.
45. Baker AH, Mehta D, George SJ, Angelini GD. Prevention of vein graft failure: potential applications for gene therapy. Cardiovasc Res. 1997;35: 442-450.
46. Mammani K, Blakis A, Morsette D, Bowcock AM, Schmuttes C, Henriet P, DeClerck YA. Structure and characterization of the human tissue inhibitor of metalloproteinases-2 gene. J Biol Chem. 1996;271: 25498-25505.
47. George SJ, Williams A, Newby AC. Essential role for platelet-derived growth factor in neointima formation in human saphenous vein in vitro. Atherosclerosis. 1996;120:227-240.
48. Apte SS, Olsen BR, Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem. 1995;270:14313-14318.
49. Forough R, Koyama M, Hasenstab D, Lea H, Clowes M, Nikkari ST, Clowes AW. Overexpression of tissue inhibitor of metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ Res. 1996;79:812-820.
50. Kenagy RD, Vergel S, Mattsson E, Bendeck M, Reidy MA, Clowes AW. The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. Arterioscler Thromb Vasc Biol. 1996;16:1373-1382.
51. George SJ, Angelini GD, Newby AC, Baker AH. Adenovirus mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointima formation in human saphenous vein. Hum Gene Ther. 1998;9:867-877.
52. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, De Carlo A, Engler JA. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993;4:197-250.